drugset / Trial / NCT01273922
Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida
Phase 1
Completed
40 enrolled
NovaDigm Therapeutics, Inc.
Cetero Research, San Antonio · collabUnited States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This randomized, double-blind, placebo-controlled study is a first-in-human Phase 1 study using two dose levels of an investigational vaccine directed against S. aureus and Candida. The study is designed to evaluate the safety, tolerability and immunogenicity of the investigational vaccine, NDV-3
Timeline
- Start
- 2011-01
- Primary completion
- 2011-10
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NDV-3 | Vaccine | — | Intramuscular |